SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors react to a significant earnings beat and raised full-year revenue guidance, sparking intense debate over whether the stock's growth potential justifies its complex capital structure. The community is actively weighing the company's surging backlog and defense partnerships against persistent concerns regarding dilution and the influence of market makers on share price volatility.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as investors cheer its record revenue, positive EBITDA, and strategic acquisition of Goonhilly Earth Station. The stock is a focal point of intense community debate, with bulls citing multi-year growth potential and upcoming contract catalysts, while others monitor the volatility surrounding its high-volume price swings.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is seeing strong trading activity driven by a triple-digit revenue surge and increased guidance for the fiscal year, with investors debating the potential for long-term growth and the impact of upcoming reimbursement changes. The community is actively discussing the company's path to profitability, the commercial outlook for its DefenCath and Rezzayo products, and speculation regarding potential strategic moves or acquisition interest from larger dialysis providers.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is seeing heightened investor activity and volatility following the launch of a new energy subsidiary focused on battery storage systems for data centers and industrial infrastructure. The community is actively debating the company's strategic pivot toward AI-linked energy demands, with options traders heavily positioning for long-term price movement despite mixed sentiment regarding executive leadership and ongoing recall challenges.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is facing significant market volatility as investors weigh strong growth and a series of strategic partnerships against bearish sentiment driven by high short interest and macroeconomic headwinds. The community is closely watching upcoming legal catalysts, including a high-stakes antitrust damages proceeding involving PriceRunner, which many believe is a pivotal factor for the stock's future performance.

Robinhood Ventures Fund I invest in companies located in the United States. The fund focuses on a broad range of sectors and industries. It provides financing for early stage transactions.

Robinhood Ventures Fund I - Common shares of beneficial interest

Robinhood Ventures Fund (RVI) is seeing intense volatility and massive volume as retail traders speculate on its private AI-heavy portfolio, specifically its exposure to high-growth firms like Databricks and OpenAI. The community is sharply divided, with bulls viewing the fund as a rare, accessible play on pre-IPO tech giants while skeptics warn that the current market price represents an unsustainable premium to the fund's underlying net asset value.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors rally around the company's aggressive expansion into agentic AI for broadband networks and its integration into the AI-native 6G and cloud infrastructure ecosystem. The community is heavily focused on intense call option activity and potential upcoming milestones, viewing the stock as an undervalued play transitioning into a critical component of the AI supply chain.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing significant momentum as investors position themselves ahead of the upcoming AUA Annual Meeting, where the company is slated to present practice-changing extended follow-up data for its prostate cancer therapy. The community is actively discussing the stock's potential for a major re-rating, with widespread speculation regarding a potential buyout and excitement over the firm's strengthened balance sheet and upcoming BLA submission.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is experiencing significant volatility as investors weigh the company's aggressive U.S. manufacturing expansion and promising storage backlog against concerns over debt levels and soft near-term guidance. The community is actively debating the potential for an eventual share price re-rating driven by upcoming IRA manufacturing tax credits, while short sellers remain highly active amid persistent questions regarding executive leadership, balance sheet health, and the timing of asset monetization.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is surging as the market re-rates the company as a critical AI infrastructure play following better-than-expected earnings and a massive boost in hyperscaler AI orders. Investors are focused on its strategic shift toward networking, silicon, and data center connectivity, with many noting its newfound momentum as it breaks toward record highs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3

Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for...

Promising Penny Stocks To Watch Today - May 3rd

Esperion Therapeutics, SOBR Safe, JetBlue Airways, BigBear.ai, Lakewood-Amedex Biotherapeutics, Beyond Meat, and Direxion Daily AMD Bear 1X Shares are the seven Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced shares of small public companiesc...

Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces Positive...

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors PR Newswire SARASOTA, Fla...

<ul class="summary-bullets"><li>Lakewood-Amedex Biotherapeutics Chairman Doug Manion said the listing will enable the company to accelerate the development of its bisphosphocin class of compounds.</li><li>This includes the company’s lead product, Nu-3, which is being developed as a potential treatment for infected diabetic foot ulcers.</li><li>Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper stated that the company plans to initiate a Phase 2a clinical trial of Nu-3 for the treatment of iDFU.</li></ul>Shares of Lakewood-Amedex Biotherapeutics Inc. (LABT) soared more than 70% in Friday’s pre-market trade, a day after the company announced a direct listing on the Nasdaq stock exchange.Lakewood-Amedex Biotherapeutics began trading on the Nasdaq on Thursday, closing the day up over 8% and with a market capitalization of $122 million.<a href="https://stocktwits.com/symbol/LABT">Lakewood-Amedex Biotherapeutics shares</a> were up nearly 50% in Friday’s pre-market trade.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around the company trended in the ‘neutral’ territory, with message volumes at ‘extremely high’ levels. LABT was among the top-trending tickers on the platform at the time of writing.One user stated that the real test for LABT would be how it handles the $14 level on any pullback today would be the real test for the stock.<stembedurl>https://stocktwits.com/Olivia_Strickland/message/651253709</stembedurl><h2 class="st-heading-2">Chairman Says Listing Will Accelerate Development</h2>Lakewood-Amedex Biotherapeutics Chairman Doug Manion said the listing will enable the company to accelerate the development of its bisphosphocin class of compounds.This includes the company’s lead product, Nu-3, which is being developed as a potential treatment for infected diabetic foot ulcers (iDFU).Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper stated that the company plans to initiate a Phase 2a clinical trial of Nu-3 for the treatment of iDFU.Cooper added that of the 40 million diabetes patients in the U.S., around one-third develop DFU in their lifetime. He stated that the DFU will become infected in around half of these patients.“Numerous patients experience more than one of these events in their life, and antibiotic-resistant bacterial strains are a major concern for the treatment of these patients. We look forward to accelerating our work targeting this major unmet need,” Cooper added.<h2 class="st-heading-2">Early Exploratory Trials Showed No Safety Concerns, Says Company</h2>The company stated that early exploratory trials of Nu-3 at subclinical doses showed no safety concerns, while indicating a trend toward antimicrobial activity and improved wound healing.Based on these findings, the company plans to initiate a Phase 2a study to assess safety and dose response, followed by a placebo-controlled Phase 2b trial comparing different doses.The program will also evaluate the optimal administration regimen for Nu-3 gel formation in mildly infected diabetic foot ulcers, the company said.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dan-ives-intel-comeback-rocky-balboa-ai-trade-in-third-innings/cZBWzYEReTv">Dan Ives Compares Intel's Comeback To Rocky Balboa, Says AI Trade Is In Its Third Innings — 'You Follow The Capex, That's Where Investors Are'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

“We are pleased to have settled our lawsuit with the United States Department of Justice,” the LYV said in a statement as its stock closed higher. 

This Newly Listed Biotech Is Soaring – Retail Says $14 Is The Line In The Sand

Lakewood-Amedex Biotherapeutics started trading on the Nasdaq on Thursday, closing the day with gains of over 8% and a market capitalization of $122 million.

LABT Stock Soars 50% After Nasdaq Debut – Retail Says $14 Is The Line In The Sand

Equity

Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"

Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol 'LABT' Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the...

Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. Its anti-infective products targeted certain viral diseases like avian influenza, Epstein Barr Virus (EBV), and hepatitis B and C. The company was founded by Roderic Dale on July 11, 2006 and is headquartered in Bradenton, FL.

Lakewood-Amedex Biotherapeutics Inc.

Buying for a long-term investment

Buying for a short-term trade

Trading around the volatility

Avoiding it 

Cerebras ($CRBS) IPO day is Thursday, how are you playing it?  
 
Drop a comment with your strategy.

Current Price	$2.66
Prev Close	$2.95
Open	$2.83
Dividend Yield	N/A
50-Day Moving Average	$4.15
Beta	0.00
Avg. Volume	954,749.12
PE Ratio	-4.28

52-Week High	$9.82
52-Week Low	$2.58
Market Capitalization	$41.36M
EPS (Annual)	-$0.84
Price to Book	-10.49
Revenue Per Employee	$0.00

LABT
Lakewood-Amedex Biotherapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest LABT News

LABTLakewood-Amedex Biotherapeutics Inc.